Efficacy and safety of omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneu-monia in children
- VernacularTitle:奥马环素治疗儿童大环内酯类药物无反应性肺炎支原体肺炎的疗效与安全性
- Author:
Qingmei ZHU
1
;
Jing WANG
2
;
Lili SHI
3
;
Dongliang YANG
1
;
Jiawei HE
1
;
Jing SHEN
1
;
Jianhua YANG
1
Author Information
1. Dept. of Pharmacy/Key Laboratory of Clinical Drug Research in Xinjiang，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830054，China
2. Dept. of Public Health and Infection Management，Sixth People’s Hospital of Xinjiang Uygur Autonomous Region，Urumqi 830013，China
3. School of Pharmacy，Xinjiang Medical University，Urumqi 830054，China
- Publication Type:Journal Article
- Keywords:
omadacycline;
children;
macrolides;
drug resistance;
Mycoplasma pneumoniae pneumonia;
clinical efficacy
- From:
China Pharmacy
2026;37(4):480-485
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the efficacy and safety of omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia （MUMPP） in children. METHODS A retrospective study was conducted on children aged 1-18 years old with MUMPP who were hospitalized in the Department of Pediatrics， the First Affiliated Hospital of Xinjiang Medical University from January 2022 to June 2025. According to the selection of secondary antibiotics after 72 h of initial treatment with macrolides， they were divided into the omadacycline group and the doxycycline group. Based on conventional treatment， children in the omadacycline group were given intravenous infusion of 2.4 mg/kg （once daily） of omadacycline tosylate， while children in the doxycycline group were given oral doxycycline hydrochloride tablets at 2 mg/kg （twice daily）. The efficacy and safety were compared between the two groups of pediatric patients. Univariate analysis and multivariate Logistic regression analysis were performed on clinical efficacy， and subgroup analysis along with multiple sensitivity analyses were conducted to verify the robustness of the conclusions. RESULTS A total of 284 children with MUMPP were included in this study， with 142 in the omadacycline group and 142 in the doxycycline group. In terms of efficacy， although the hospitalization time of children in the omadacycline group was longer than that in the doxycycline group （ P ＜0.05）， the lung lesion absorption rate and clinical efficacy were significantly higher or better than those in the doxycycline group （ P ＜0.05）. The results of multivariate Logistic regression analysis showed that medication （OR＝5.300， 95%CI： 2.526-11.123）， length of hospital stay （OR＝1.348， 95%CI： 1.167-1.556）， and medication duration （OR＝1.422， 95%CI： 1.169-1.729） were influencing factors of clinical efficacy （ P ＜0.05）. The subgroup analysis results showed that the clinical efficacy of omadacycline was significantly better than that of doxycycline in all subgroups （ P ＜0.05）. The results of multiple sensitivity analysis showed that the regression coefficients B of the four models （gradually adjust variables） before and after inverse probability of treatment weighting were significantly greater than 1 （ P ＜0.05）. In terms of safety， there was no statistically significant difference in the inci dence of adverse drug reactions between the two groups of patients （ χ 2 ＝0.447， P ＝0.504）. CONCLUSIONS In the case of hospitalization and prolonged medication， the efficacy of omadacycline in treating childhood MUMPP is superior to that of doxycycline， and its safety is good.
